Tavalisse is an adult thrombocytopenia treatment drug owned by Rigel Pharms Inc. It contains the active ingredient fostamatinib disodium. It was first approved for market use on 17 April, 2018, and it's available in tablet and oral dosage forms. The drug has total of 14 patents, none of which have expired till now.
Drug patent challenges against Tavalisse can start from 17 April, 2022. The generic version of Tavalisse is likely to be released after 27 July, 2032, which marks the expiration date of its last patent.
Tavalisse is used for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP). It has shown effectiveness in patients who have had an insufficient response to a previous treatment. Its effectiveness comes from its active ingredient, fostamatinib disodium.
Tavalisse has a total of 14 patents. Of these, none have expired yet. The patents cover various aspects of the drug, including the prodrugs and the formulations. The last patent will expire on 27 July, 2032. The generics of Tavalisse will become available after this date. Below are the details of the patent: